THERAPY DOSSIER · th-6052c716c652

Interleukin-6

Biologic · No confident ChEMBL small-molecule/drug match; IL-6 is a pro-inflammatory cytokine (trials target the IL-6 pathway, not administer IL-6)

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: No confident ChEMBL small-molecule/drug match; IL-6 is a pro-inflammatory cytokine (trials target the IL-6 pathway, not administer IL-6)
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25433073 ↗2015Reported benefit

Protection of intestinal injury during heat stroke in mice by interleukin-6 pretreatment.

MouseOtherC57BL/6MaleIntraperitoneal0.6 microgramsTwo hours before hyperthermia

Model: Severe hyperthermia (heat stroke) with incremental heating to a maximum core temperature of 42.4 degrees C, causing intestinal injury

IL-6 pretreated mice required about 25 minutes longer to reach maximum core temperature, were protected from duodenal villus injury and swelling, showed reduced gastrointestinal permeability and had significantly lower plasma TNF-alpha, MCP-1, RANTES and KC.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…